Cargando…

Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA

INTRODUCTION: This real-world study compared glycemic effectiveness, treatment durability, and treatment costs with canagliflozin 300 mg versus any dose of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes mellitus (T2DM) in the USA. RESEARCH DESIGN AND METHODS: A re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singhal, Mukul, Tan, Hiangkiat, Coleman, Craig I, Han, Michelle, Nguyen, Chi, Ingham, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Epidemiology/Health Services Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861096/ https://www.ncbi.nlm.nih.gov/pubmed/31798890 http://dx.doi.org/10.1136/bmjdrc-2019-000704

Ejemplares similares

Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2020)

Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
por: Kahkoska, Anna R., et al.
Publicado: (2021)

Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
por: Sherr, Jennifer L., et al.
Publicado: (2016)

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
por: Rickels, Michael R., et al.
Publicado: (2016)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes
por: Thieu, Vivian T, et al.
Publicado: (2019)

Effect of periodontal treatment on diabetes-related healthcare costs: a retrospective study
por: Smits, Kirsten P J, et al.
Publicado: (2020)

New directions in incidence and prevalence of diagnosed diabetes in the USA
por: Benoit, Stephen R, et al.
Publicado: (2019)

Concurrent Use of Teneligliptin and Canagliflozin Improves Glycemic Control with Beneficial Effects on Plasma Glucagon and Glucagon-Like Peptide-1: A Single-Arm Study
por: Noda, Tomoho, et al.
Publicado: (2019)

Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
por: Mouhammad, Zaynab Ahmad, et al.
Publicado: (2022)

Is there a role for glucagon‐like peptide‐1 receptor agonists in the treatment of male infertility?
por: Cannarella, Rossella, et al.
Publicado: (2021)

Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
por: Raven, Lisa M, et al.
Publicado: (2022)

Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?
por: Bloomgarden, Zachary
Publicado: (2023)

Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy
por: Kobori, Toshiko, et al.
Publicado: (2023)

Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Berman, Casey, et al.
Publicado: (2023)

Diabetes mellitus among adults with tuberculosis in the USA, 2010–2017
por: Armstrong, Lori R, et al.
Publicado: (2020)

Diabetes as an increasingly common comorbidity among patient hospitalizations for tuberculosis in the USA
por: Zahr, Roula S, et al.
Publicado: (2016)

Correlates of second-line type 2 diabetes medication selection in the USA
por: Ackermann, Ronald T, et al.
Publicado: (2017)

Trends in type 2 diabetes detection among adults in the USA, 1999–2014
por: Geiss, Linda S, et al.
Publicado: (2018)

Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression
por: Detka, Jan, et al.
Publicado: (2021)

Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes”
Publicado: (2022)

Early treatment revisions by addition or switch for type 2 diabetes: impact on glycemic control, diabetic complications, and healthcare costs
por: Schwab, Phil, et al.
Publicado: (2016)

Incidence of diabetes and prediabetes and predictors of glycemic change among South Asians in the USA: the MASALA study
por: Gujral, Unjali P, et al.
Publicado: (2020)

Patterns and correlates of use of evidence-based interventions to control diabetes by local health departments across the USA
por: Tabak, Rachel G, et al.
Publicado: (2018)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population
por: Willey, Vincent, et al.
Publicado: (2018)

Long-term mortality among kidney transplant recipients with and without diabetes: a nationwide cohort study in the USA
por: Harding, Jessica L, et al.
Publicado: (2021)

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Cho, Young Min, et al.
Publicado: (2013)

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
por: Kalra, Sanjay, et al.
Publicado: (2016)

An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning
por: Rameshrad, Maryam, et al.
Publicado: (2020)

It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Oberle, Megan M., et al.
Publicado: (2019)

Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review)
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Lifestyle and Metformin Interventions Have a Durable Effect to Lower CRP and tPA Levels in the Diabetes Prevention Program Except in Those Who Develop Diabetes
por: Goldberg, Ronald B., et al.
Publicado: (2014)

Trends in inpatient admissions and emergency department visits for heart failure in adults with versus without diabetes in the USA, 2006–2017
por: Harding, Jessica L, et al.
Publicado: (2021)

Does cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA
por: Delling, Francesca N, et al.
Publicado: (2019)

Insulin pricing and other major diabetes-related concerns in the USA: a study of 46 407 tweets between 2017 and 2019
por: Ahne, Adrian, et al.
Publicado: (2020)

Racial and ethnic disparities in the refusal of surgical treatment in women 40 years and older with breast cancer in the USA between 2010 and 2017
por: Fwelo, Pierre, et al.
Publicado: (2022)

Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado
por: McQueen, R. Brett, et al.
Publicado: (2020)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_434ta711echmb9m1fuv58ju79r